RxDoctor Payments Data

Marc Schechter, DO

Family Medicine · Plainview, NYNPI 1255436945

Payments from drug & device makers

$1,819in general payments, 2019–2025

Across 78 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$395
  • Novartis$288
  • Pfizer$223
  • GSK$205
  • Amgen$177
  • Merck$105
  • plus $427 from 12 others

What the payments were for

  • Food & beverage$1,813100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie14$395
Novartis13$288
Pfizer13$223
GSK7$205
Amgen8$177
Merck5$105
Biohaven Pharmaceuticals, Inc.1$88
Eisai Inc.3$61
Esperion Therapeutics, Inc.3$57
Almatica Pharma LLC2$54
Boehringer Ingelheim1$41
Vistapharm, Inc.2$26
Insightec,inc1$23
Clarus Therapeutics Inc.1$20
Novo Nordisk1$17
Abbott1$17
Sanofi Pasteur Inc.1$15
Althera Pharmaceuticals LLC1$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,819 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$138,545
Medicare patients
339
Services billed
2,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin21$30,392
MounjaroTirzepatide23$29,081
Rosuvastatin Calcium242$3,566
Levothyroxine Sodium143$2,390
SynthroidLevothyroxine Sodium51$2,046
Atorvastatin Calcium203$1,988
Losartan Potassium129$1,638
Metoprolol Succinate126$1,585
Valsartan47$1,406
Armour ThyroidThyroid,pork15$1,196
Simvastatin86$1,058
Amlodipine Besylate151$1,044
Ezetimibe41$1,037
Tamsulosin Hcl65$1,029
Metformin Hcl95$876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$41$30,39221 claims
AbbVieSynthroid, Armour Thyroid$395$3,24366 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Plainview

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →